Market Mover: Kezar Life (KZR) Rises at Midday June 21

Equities Staff  |

Kezar Life Sciences Inc (NASDAQ: KZR) shares climbed 7.94%, or $0.42 per share, as on 12:00:37 est today. Opening the day at $4.87, 294,419 shares of Kezar Life have exchanged hands and the stock has traded between $5.82 and $5.40.  

This year the company has a YTD change of 68.36%.

Kezar Life is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on Kezar Life visit the company profile.

About Kezar Life Sciences Inc

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

To get more information on Kezar Life Sciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Kezar Life Sciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content